The OAB Therapeutics Market is Forecast to Decline up to 2019

Tuesday 21 February 2012, Amsterdam

The report is an essential source of information and analysis on the global Overactive Bladder Therapeutics market. The report identifies the key trends shaping and driving the global Overactive Bladder Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Overactive Bladder Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The OAB Therapeutics Market is Forecast to Decline up to 2019

They estimated the global Overactive Bladder (OAB) therapeutics market to be worth $1.8 billion in 2011. However, it is expected to decline to $1.3 billion by 2019 at a Compound Annual Growth Rate (CAGR) of (4.3%). This decline is primarily attributable to the patent expiries of key drugs in the OAB therapeutics market such as Oxytrol, Enablex/Esmelex (darifenacin), Toviaz (fesoterodine), Ditropan/Ditropan XL (oxybutynin), Detrol/Detrol LA (tolterodine) and VESIcare (solifenacin). Whilst there will be an increase in population and the launch of new products (Anturol Gel and YM178) during this period, they are insufficient to negate the impact of the aforementioned patent expiries. The market remains well-served with the current marketed products, most of which are moderately efficacious in their respective target areas but weak safety profiles are a concern.

See figure: OAB Therapeutics Market, Global, Revenue and Forecast ($m), 2006-2019

Current Treatment Options Leave Moderate level of Unmet Need

At present the OAB therapeutics market is made up of drugs such as Enablex/Esmelex (darifenacin), Toviaz (fesoterodine) Detrol (tolterodine), VESIcare (solifenacin), Sanctura XR (trospium), Ditropan XL (oxybutynin) and Botox, which all possess moderate efficacy profiles, but the inability of these drugs to offer absolute patient compliance, patient satisfaction and drug safety leaves an unmet need in the market. The low patient compliance of the currently marketed drugs is due to their limited efficacy and the adverse effects associated with them. The currently marketed drugs all possess similar profiles in terms of their mechanisms of action, safety and efficacy. Therefore, there is scope for new products with novel mechanisms of action which also provide better safety and efficacy profiles. The entry of such products would have a significant impact on the future OAB therapeutics market. .

A Weak Pipeline is Unlikely to Contribute to the OAB Therapeutics Market during the Forecast period

The OAB therapeutics developmental pipeline has 32 molecules in various phases of clinical and preclinical development. There are five molecules in late-stage New Drug Application (NDA filed and Phase III) development. Although, there are 10 first-in-class molecules (FIC) in the OAB pipeline, only one (YM178) is in the NDA filing stage. The launch of YM178 is expected to increase the valuation of the OAB therapeutics market. It is yet to be seen if and by how much it will increase patient compliance and adherence, which is an important unmet need in the OAB therapeutics market. The rest of the FIC molecules are in early phases of development and are not expected to have any impact on the OAB therapeutics market during the forecast period (2011- 2019). There is still significant untapped potential within the market as the currently available therapies do not provide sufficient comfort to the needs of patients. The market is demanding new entrants with novel treatments and therapy designs to improve the overall patient and physician satisfaction levels.